Page last updated: 2024-11-13

clp257

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

CLP257: a chloride extrusion enhancer that targets KCC2; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID44188931
SCHEMBL ID3397181
MeSH IDM0590728

Synonyms (17)

Synonym
SCHEMBL3397181
SKCADXVKQRCWTR-GHXNOFRVSA-N ,
(5z)-2-(1,2-diazinan-1-yl)-5-[(4-fluoro-2-hydroxyphenyl)methylidene]-4,5-dihydro-1,3-thiazol-4-one
AKOS025142066
(5z)-5-[(4-fluoro-2-hydroxyphenyl)methylene]-2-(tetrahydro-1-(2h)-pyridazinyl)-4(5h)-thiazolone
clp 257
1181081-71-9
clp257, >=98% (hplc)
clp257
CS-0033000
HY-110143
clp-257
EX-A5106
(5z)-2-(diazinan-1-yl)-5-[(4-fluoro-2-hydroxyphenyl)methylidene]-1,3-thiazol-4-one
D95618
MS-24452
(z)-5-(4-fluoro-2-hydroxybenzylidene)-2-(tetrahydropyridazin-1(2h)-yl)thiazol-4(5h)-one
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (7)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's6 (85.71)24.3611
2020's1 (14.29)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 21.78

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index21.78 (24.57)
Research Supply Index2.08 (2.92)
Research Growth Index4.56 (4.65)
Search Engine Demand Index18.60 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (21.78)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other7 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]